Mylan MYL

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Gilead licenses Sovaldi to Indian firms

      Headlines

      Mon, 15 Sep 2014

      global infected population). The Indian companies are: Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories, Ltd., Sequent Scientific Ltd., and Strides Arcolab Ltd. Under the terms of the

    2. BRIEF-Gilead Sciences says licensed Hep C drug sovaldi to 7 companies

      Headlines

      Mon, 15 Sep 2014

      * Says licensed Hep C drug Sovaldi to 7 companies including Cipla Ltd, Mylan laboratories , Ranbaxy

    3. FDA tentatively approves Mylan's HIV combo

      Headlines

      Sat, 13 Sep 2014

      The FDA grants tentative approval for Mylan 's (NASDAQ: MYL ) emtricitabine and tenofovir disoproxil fumarate combination tablets (200 mg/300 mg) co-packaged with nevirapine tablets

    4. Strong Portfolio Will Drive Growth For Mylan

      Headlines

      Thu, 11 Sep 2014

      By Chronic Bull : Mylan (NASDAQ: MYL ) was reiterated as a buy by the analysts ..... several branded medications. Moreover, Mylan provides a wide range of antiretroviral ..... depend. According to IMS Health , Mylan currently has 294 abbreviated new drug

    5. UPDATE 2-S.Africa's Aspen to sell U.S. drug rights to Mylan for up to $300 mln

      Headlines

      Wed, 10 Sep 2014

      JOHANNESBURG, Sept 10 (Reuters) - Aspen Pharmacare is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.

    6. Mylan secures U.S. rights to DVT drug

      Headlines

      Wed, 10 Sep 2014

      Mylan (NASDAQ: MYL ) acquires the U.S. rights to Arixtra ..... prophylaxis of deep vein thrombosis (DVT). Mylan is already selling Arixtra via an interim ..... generic Arixtra but will transition it to Mylan by year end. Under the terms of the agreement

    7. New Morningstar Analyst Report for Mallinckrodt PLC

      Stock Reports

      Tue, 9 Sep 2014

      While we believe an acquisition is possible, we would caution against investors speculating on a takeover, given that Mylan /Abbott and Salix/Cosmo have recently shown the market ways to drastically lower tax rates without acquiring an Irish

    8. Hospira may cut sales staff after losing Precedex case

      Headlines

      Mon, 8 Sep 2014

      motion for a temporary restraining order against the FDA, Mylan ( MYL +2.1% ) and Par Sterile Products against the introduction ..... Appeals for the Fourth Circuit. Not known for waiting, Mylan restarts the launch of its generic version. Despite the

    9. New Morningstar Analyst Report for Actavis PLC

      Stock Reports

      Fri, 5 Sep 2014

      marks for shareholder stewardship. Historically, Actavis has avoided an aggressive acquisition strategy like Teva and Mylan , but management has proved adept at finding niche generic opportunities, including Lipitor, Lovenox, and Concerta, which

    10. Teva Proves You Cannot Escape The Patent Cliff

      Headlines

      Thu, 4 Sep 2014

      and one fifth of Teva's revenue could vanish. The Copaxone patent expired on May 24, 2014, which caused Mylan Inc. (NASDAQ: MYL ) Novartis AG (NYSE: NVS ) , and Momenta Pharmaceuticals (NASDAQ: MNTA ) to apply to the US Food and Drug

    « Prev12345Next »
    Content Partners